Fusion Pharmaceuticals
Targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers. Learn more
Launch date
Employees
Market cap
CAD2.5b
Enterprise valuation
CAD2.3b (Public information from May 2024)
Share price
$21.55 FUSN
Hamilton Ontario (HQ)
Authorizing premium user...